Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Erelzi. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Etanercept-Szzs (sold as Erelzi), first approved Aug 30, 2016, with 3 new uses approved and 0 published complete response letters.
EnbrelDrugs with a new additional indication for the treatment of rheumatoid arthritis (including prevention of structural joint damage) in patients who have not… · Pfizer Japan Inc. · Mar 21, 2012
EnbrelDrugs with a new dosage indicated for the treatment of rheumatoid arthritis (for use only in patients who have not sufficiently responded to conventional… · Wyeth K.K. · Feb 5, 2010
EnbrelA drug with a new indication and a new dosage for the treatment of polyarticular-course juvenile idiopathic arthritis (for use only in patients who have not… · Wyeth K.K. · Jul 7, 2009
Applications
NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Sandoz